Because of its immunomodulatory and anticancer activities, IFN; has been used as an anticancer drug in several clinical studies, unfortunately with modest results. Attempts to increase the response by increasing the dose or by repeated continuous injection often resulted in lower efficacy, likely due to counterregulatory effects. We show here that targeted delivery of low doses of IFN; to CD13, a marker of angiogenic vessels, can overcome major counterregulatory mechanisms and delay tumor growth in two murine models that respond poorly to IFN;. Tumor vascular targeting was achieved by coupling IFN; to GCNGRC, a CD13 ligand, by genetic engineering technology. The doseresponse curve was bell-shaped. Maximal effects were induced with a dose of 0.005 A Ag/kg, about 500-fold lower than the dose used in patients. Nontargeted IFN; induced little or no effects over a range of 0.003 to 250 A Ag/kg. Studies on the mechanism of action showed that low doses of targeted IFN; could activate tumor necrosis factor (TNF)-dependent antitumor mechanisms, whereas high doses of either targeted or nontargeted IFN; induced soluble TNFreceptor shedding in circulation, a known counterregulatory mechanism of TNF activity. These findings suggest that antitumor activity and counterregulatory mechanisms could be uncoupled by tumor vascular targeting with extremely low doses
Introduction
A large body of evidence suggests that IFNg, a pleiotropic cytokine mainly produced by T lymphocytes and natural killer cells (1, 2) , could promote antitumor responses (3) (4) (5) (6) (7) (8) (9) (10) . For instance, IFNg could induce antiproliferative and proapoptotic effects on many tumor cell types (11) , inhibit tumor angiogenesis (8, (12) (13) (14) , and activate natural killer cells and macrophages to kill a variety of tumor cell targets (11) . IFNg is also an important regulator of CD4 + T helper cells (15, 16) , is the major physiologic macrophage-activating factor (17) (18) (19) , and can augment the expression of MHC-I and -II on cancer and endothelial cells (2, 20, 21) . Within tumor stroma, IFNg can induce cytokine and chemokine secretion, including IP-10, an angiostatic protein and a chemoattractant factor for lymphocytes and monocytes (11, 12) . Evidence has been obtained to suggest that IFNg produced by tumor-infiltrating macrophages plays a role in tumor blood vessel destruction (22) . Combined treatment of endothelial cells with IFNg and tumor necrosis factor (TNF)-a results in synergistic cytotoxic effects, likely important for tumor vasculature destruction (23) . IFNg can also increase the production of TNF by activated macrophages, as well as the expression of TNFreceptors in various cell types (24) (25) (26) . As a consequence of these effects on tumor vasculature and on cells of the immune system, IFNg can activate inflammatory/immune responses against established tumors and inhibit tumor growth (27) .
The antiproliferative, angiostatic, and immunomodulatory activity of IFNg make this cytokine an attractive anticancer agent. For this reason, several clinical studies have been done with this cytokine. Unfortunately, the response rates observed in early studies, based on doses that approached the maximal tolerated dose, were very low (28) (29) (30) . Studies in animal models showed that the antitumor activity of IFNg exhibits a bell shaped dose-response curve (6) . Subsequent studies, carried out in patients, showed that induction of immune-activation markers also exhibit a bell-shaped dose-response curve (31) (32) (33) . This suggests that optimal biological effects could be induced by doses below the maximum tolerated dose. Interestingly, the results of a phase III study on ovarian cancer patients showed that inclusion of relatively low doses of this cytokine (100 Ag) in first-line chemotherapy could prolong progression-free survival (34) . Higher response rates were also observed in melanoma patients treated with the low-dose weekly regime compared with higher doses and more frequent schedules (35) . However, no difference in outcome was observed in a recent phase III study in patients with renal-cell carcinoma treated with low doses of IFNg (60 Ag/m 2 once every week), as compared with placebo (36) .
The results of preclinical and clinical studies suggest that attempts to increase the antitumor efficacy by increasing the dose and the exposure to IFNg could actually result in higher toxicity and lower efficacy, likely because of induction of counterregulatory mechanisms. Therefore, the development of new strategies that overcome the untoward effects of IFNg and bypass counterregulatory mechanisms could be of great experimental and clinical value.
The biological effects induced by IFNg on tumor stroma and blood vessels provide the rationale for a tumor vasculature targeting approach. To this aim, we have fused, by recombinant DNA technology, the COOH terminus of murine IFNg with the NH 2 terminus of Gly-Cys-Asn-Gly-Arg-Cys (GCNGRC), a ligand of a CD13 (aminopeptidase N) isoform expressed by angiogenic vessels (37, 38) . The CNGRC peptide, previously identified by in vivo panning of peptide-phage display libraries (39) , has proven useful for targeting chemotherapeutic drugs, proapoptotic peptides and TNF to tumor blood vessels (38) (39) (40) (41) (42) (43) (44) (45) . We show here that targeted delivery of minute amounts (picogram doses) of IFNg-GCNGRC conjugate (called IFNg-NGR) to tumor vasculature could be a valuable strategy for overcoming major counterregulatory mechanisms and inducing antitumor effects.
Materials and Methods
Cell lines and reagents. EA.hy926 cells (human endothelial cells fused with human lung carcinoma A549 cells (46) were obtained from Dr. Elisabetta Ferrero (San Raffaele H Scientific Institute, Milan, Italy). EA.hy926 cells and murine WEHI-164 fibrosarcoma cells (Sigma-Aldrich, Milan, Italy) were cultured in DMEM (Euroclone, Milan, Italy) supplemented with 2 mmol/L glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, and 10% fetal bovine serum. Murine RMA lymphoma (47) and B16/F1 melanoma cells were cultured as described previously (48) . Monoclonal antibody (mAb) R3-63 (rat anti-mouse CD13; ref. 49 ) was from Acris Antibodies GmbH (Hiddenhausen, Germany), goat anti-mouse-FITC secondary antibody was from Sigma-Aldrich, mAb Y-3 (mouse anti-H-2K b ) and mAb 19E12 (rat anti-mouse Thy1.1) were provided by Dr. Paolo Dellabona (San Raffaele Scientific Institute, Milan, Italy), and mAb V1q (rat anti-murine TNF) was kindly supplied by Dr. Daniela N. Mannel (University of Regensburg, Germany). Recombinant murine IFNg was from PeproTech, London, United Kingdom. Human TNF and the CNGRCG-TNF conjugate (NGR-TNF) were prepared as described previously (41) .
Preparation of IFN;-NGR and IFN;-C136S. The cDNA coding for murine IFNg-NGR (IFNg-NGR; IFNg 4-135 fused with the NH 2 terminus of SGCNGRC) was obtained by reverse transcriptase-PCR on total RNA purified from the splenocytes of C57BL/6 mice (Harlan, Italy). Before RNA extraction, the splenocytes were stimulated for 20 hours with 10 Ag/mL lipopolysaccharide in RPMI (Euroclone) supplemented with 2 mmol/L glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, 0.25 Ag/mL amphotericin-B, and 10% fetal bovine serum. Reverse transcription-PCR was done using the following primers: ATATCTACATATGCACGGCACAGTCATTGAAAGCC ( forward primer); TCGGATCCTCAGCAACGGCCGTTGCAGCCGGAGC-GACTCCTTTTCCGCTTCCTGAGGC (reverse primer). Primer sequences were designed to include the NdeI and BamHI restriction sites for cloning in pET11 plasmid (Novagen, Madison, WI). The cDNA coding for murine IFNg-C136S (an IFNg 4-136 -mutant with Cys 136 replaced with Ser) was prepared by PCR on the IFNg-NGR plasmid, using ATATCTACATATG-CACGGCACAGTCATTGAAAGCC ( forward primer) and TCGGATCCTCAG-GAGCGACTCCTTTTCCGC (reverse primer), and cloned in pET11.
Both cDNA were expressed in BL21(DE3) E. coli cells (Novagen). The products were purified from cell extracts by ammonium sulfate precipitation and hydrophobic interaction chromatography on PhenylSepharose 6 Fast Flow (Amersham Biosciences Europe GmbH, Freiburg, Germany), followed by ion exchange chromatography on DEAE-Sepharose Fast Flow (Amersham). The products were gel-filtered through an HRSephacryl S-300 column (1,025 mL; Amersham) preequilibrated with 150 mmol/L sodium chloride, 50 mmol/L sodium phosphate (pH 7.3), containing 5% sucrose. Fractions corresponding to dimeric products were pooled, filtered through a 0.22 Amol/L filter, and stored at À20jC. All solutions used in the purification steps were prepared with sterile and endotoxin-free water (S.A.L.F. Laboratorio Farmacologico SpA, Bergamo, Italy). Protein concentration was measured using the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). About 3 to 4 mg of purified proteins were recovered from 1 L of E. coli culture. Protein purity and identity were checked by SDS-PAGE.
Fluorescence-activated cell sorting analysis. Murine B16/F1 melanoma cells were plated in 24-well plates (2 Â 10 5 cells per well in 1 mL of culture medium). After 1 hour, the cells were treated with various amounts of IFNg or IFNg-NGR for 20 hours at 37jC, 5% CO 2 . Expression of MHC class I on cells was then assessed by fluorescence-activated cell sorting analysis as follows: the cells were detached by treatment with trypsin-EDTA, washed and resuspended in 138 mmol/L sodium chloride, 2.7 mmol/L potassium chloride, 10 mmol/L sodium phosphate (pH 7.3; PBS) containing 2% fetal bovine serum and 2 Ag/mL mAb Y-3 (anti-H-2K b ) and incubated for 1 hour on ice. After washing with PBS, the cells were incubated with goat anti-mouse-FITC secondary antibody (1:100 in PBS containing 2% FCS, 30 minutes on ice), washed, fixed with 4% formaldehyde in PBS, and analyzed by fluorescence-activated cell sorting.
EA.hy926 cell adhesion assay. Polyvinyl chloride microtiter plates (Falcon code #3912, Becton Dickinson, Franklin Lakes, NJ) were coated with 30 Ag/mL IFNg-NGR or IFNg-C136S [50 AL/well in 150 mmol/L sodium chloride, 50 mmol/L sodium phosphate (pH 7.3), at 4jC overnight]. After washing with 0.9% sodium chloride, each well was filled with DMEM containing 2% bovine serum albumin (45 minutes at 37jC), to block the uncoated surface, and washed again. EA.hy926 cells in DMEM culture media (100 AL) were then added to the plates (3 Â 10 4 cells per well). After incubation (1-1.5 hours) at 37jC, 5% CO 2 , unbound cells were removed by washing with DMEM. Adherent cells were fixed with 3% paraformaldehyde, 2% sucrose in PBS (pH 7.3), and stained with 0.5% crystal violet (Fluka Chemie, Buchs, Switzerland). Adherent cells were quantified by measuring the absorbance of each well at 540 nm, using a microplate reader.
Soluble tumor necrosis factor receptor assays. Soluble p55-TNF receptor (sTNF-R1) and soluble p75-TNF receptor (sTNF-R2) in animal sera were measured by ELISA as previously described (50) .
In vivo studies. Studies on animal models were approved by the Ethical Committee of the San Raffaele H Scientific Institute and done according to the prescribed guidelines. C57BL/6 mice or BALB/c (Harlan), 8 weeks old, were challenged with s.c. injection in the left flank of 7 Â 10 4 RMA or 10 6 WEHI-164 living cells, respectively; 6 to 10 days later, mice were treated i.p. with IFNg, IFNg-NGR, or IFNg-C136S solutions (100 AL). All proteins were diluted with 0.9% sodium chloride containing 100 Ag/mL endotoxin-free human serum albumin (Farma-Biagini SpA, Lucca, Italy). Tumor growth was monitored daily by measuring tumor volumes with calipers as previously described (51) . Animals were sacrificed before tumors reached 1.0 to 1.5 cm in diameter. Tumor sizes are shown as mean F SE ( five animals per group).
Results
Production and characterization of IFN;-NGR and IFN;-C136S. Murine IFNg is a homodimeric protein of 136 residues characterized by the presence of two cysteines in the NH 2 -terminal region (Cys-Tyr-Cys) and one cysteine at the COOH terminus (52, 53) . We have fused the COOH terminus of IFNg (lacking the NH 2 -and COOH-terminal cysteines) to the NH 2 terminus of (S)GCNGRC by recombinant DNA technology. NH 2 -terminal cysteines were omitted and Cys 136 was replaced with a serine to reduce the risk of disulfide bridge formation with the GCNGRC targeting domain. The final product was called IFNg-NGR. In parallel, the IFNg 4-135 -C136S mutant (called IFNg-C136S) was also prepared (see Fig. 1A for a schematic representation of these products). Both proteins were purified by hydrophobic interaction chromatography, ion exchange, and gel-filtration chromatography. Only fractions corresponding to dimeric species were collected during gel-filtration chromatography. The purity and identity of both products were characterized by SDS-PAGE, gel-filtration HPLC, and mass spectrometry. Reducing and nonreducing SDS-PAGE of IFNg-NGR and IFNg-C136S showed a single band of about 16 kDa, as expected for monomeric subunits (Fig. 1B) . The molecular mass of subunits, as measured by electrospray mass spectrometry, was 16,225.2 F 2.3 and 15,635.0 F 1.3 Da, respectively, corresponding to products with unprocessed NH 2 -terminal methionine (expected 16,225.5 and 15,636.8 Da, respectively). Analytic gel-filtration chromatography showed that IFNg-NGR and IFNg-C136S were homogeneous and characterized by a hydrodynamic volume of about 30 to 35 kDa, corresponding to dimers (Fig. 1C) .
Biological activity of IFN;-NGR in vitro . The functional properties of effector and targeting domains of IFNg-NGR, i.e., the IFNg and GCNGRC domains, were first investigated using in vitro biological assays. To assess whether the IFNg domain was functional, we compared the effect of various doses of IFNg-NGR and IFNg on MHC class I and II expression on murine B16/F1 cells. Fluorescence-activated cell sorting analysis of treated cells showed that both proteins could induce MHC-I expression with similar potency ( Fig. 2A and B) . IFNg-C136S induced MHC-I in a similar manner and similar results were obtained for MHC-II (data not shown). These results indicate that replacement of Cys 136 with Ser and fusion of IFNg-C136S with GCNGRC do not prevent folding, dimerization, or binding to IFNg receptors.
The accessibility and functional properties of the NGR domain were also investigated. We have previously shown, by immunohistochemical analysis of renal cell carcinoma tissue sections, that peptides and drug conjugates containing the CNGRC motif can inhibit the binding of the anti-human CD13 mAb WM-15 to tumor-associated vessels (38) . Competitive binding experiments with IFNg-NGR and IFNg showed that IFNg-NGR, but not IFNg, could compete the binding of mAb WM-15 to tumor vessels (data not shown), suggesting that IFNg-NGR could interact with CD13 expressed in tumor vessels. Considering that peptides containing the NGR motif can also interact with avh3-and a5h1-integrines with low affinity (54, 55) and inhibit avh3-and avh5-integrinmediated cell adhesion (56) we have also analyzed the effects of IFNg-NGR and IFNg-C136S in a cell adhesion assay. To this aim, the adhesion of endothelial-epithelial EA.hy926 hybrid cells to microtiter wells coated with IFNg-NGR or IFNg-C136S was studied (Fig. 3) . In parallel, we also analyzed cell adhesion to CNGRCG-TNF (called NGR-TNF), a conjugate with a functional NGR domain (41, 42) . As expected, we observed adhesion of EA.hy926 cells to microtiter plates coated with NGR-TNF or IFNg-NGR, but not with TNF or with IFNg-C136S (Fig. 3) . Cell adhesion was not inhibited by mAb WM15 (data not shown), suggesting that this effect was likely mediated by integrins and not by CD13. These results, collectively, suggest that both IFNg and CNGRC domains are properly folded and accessible for the interaction with membrane receptors.
Antitumor activity and toxicity of IFN;-NGR in vivo . The antitumor activity of IFNg-NGR, IFNg-C136S, or IFNg against s.c. RMA lymphoma and WEHI-164 fibrosarcoma was investigated in immunocompetent mice. Various doses of each cytokine, ranging from 0.03 to 5000 ng were given (i.p.) to tumor-bearing C57BL6 (RMA) or BALB/c (WEHI-164) mice. Administration of 0.1 or 0.3 ng of IFNg-NGR to RMA tumor-bearing mice, 10 days after tumor implantation, was sufficient to induce significant antitumor effects ( Fig. 4A and B) . The antitumor effect decreased when the dose was increased to 3 or 300 ng (Fig. 4B) or when the dose was decreased to 0.03 ng (data not shown), indicating that the dose-response curve of IFNg-NGR is bell-shaped. Thus, maximal effects were achieved with 0.1 ng (0.005 Ag/kg). No loss of body weight was induced by any tested dose ( Fig. 4A and B, bottom) . This suggests that IFNg-NGR could induce antitumor effects without causing major toxic effects. No significant antitumor effects were observed when IFNg was given at doses ranging from 0.3 to 300 ng (Fig. 4B, middle) or when IFNg-C136S was used (data not shown).
A bell-shaped dose-response curve was also observed in the WEHI-164 model. Again maximal effect was achieved with 0.1 ng of IFNg-NGR (Fig. 5A) , whereas lower effects were induced by 0.3 or 0.9 ng doses (Fig. 5A) . Also in this model, the antitumor effect induced by the 0.1 ng dose was not associated with loss of body weight (Fig. 5A, bottom) .
The effect of repeated administrations was then investigated. Repeated administration of IFNg-NGR produced different effects depending on dose and time schedule. For instance, we found that the antitumor effects of daily treatment with 0.03 or 0.1 ng were lower than those of biweekly treatments (Fig. 5B) . Of note, whereas the first and the second treatment with 0.1 or 0.03 ng induced an antitumor response, the subsequent daily treatments were not effective and inhibited the antitumor response induced by the first treatment (Fig. 5B, bottom) . Apparently, repeated treatment also inhibited the spontaneous transient regression observed in control animals from day 14 to day 16 in this experiment (Fig. 5B, bottom) . This phenomenon was also observed in another experiment (data not shown).
When the dose of IFNg-NGR was increased to 5000 ng (given weekly) no significant effects were observed (Fig. 5C, top) . IFNg was virtually inactive at any tested dose ( Fig. 5A and C) . Overall, these results of in vivo experiments indicate that IFNg-NGR is endowed with more potent antitumor activity than IFNg and that the antitumor activity depends on dose and time schedule.
Role of the aminopeptidase N (CD13) in the antitumor activity of IFN;-NGR. We have shown previously that a CD13 isoform expressed in tumor vessels could function as the main vascular receptor for NGR-TNF, as most of the antitumor activity of this drug is inhibited by an excess of an anti-murine CD13 mAb (mAb R3-63; refs. 38, 41) . To investigate the role of CD13 in the antitumor activity of IFNg-NGR, we have coadministered this conjugate with an excess of the anti-CD13 mAb R3-63 to RMA and WEHI-164 tumor-bearing mice. This antibody inhibited most of the antitumor effects of different doses of IFNg-NGR (3 and 0.06 ng) in these models (Fig. 6A and C) . In contrast, a control antibody (Fig. 6A) . Although we cannot exclude that integrins could also play a role in vascular targeting, the almost complete inhibition observed after CD13 neutralization suggest that CD13 plays a major role.
Role of endogenous and soluble tumor necrosis factor receptors. IFNg and TNF can exert synergistic cytotoxic effects against tumor and endothelial cells (23, 57, 58) . Keeping this in mind, we have studied the role of endogenous TNF in the IFNg-NGR antitumor activity. To this aim, RMA and WEHI-164 tumor-bearing mice were treated with IFNg-NGR alone or in combination with a neutralizing anti-murine TNF mAb (V1q). This antibody completely inhibited the antitumor effects of IFNg-NGR in both models, whereas it was inactive when given alone ( Fig. 6B and D) . Also in this experiment, the control mAb 19E12 did not inhibit the antitumor activity of IFNg-NGR. These results suggest that endogenous TNF is critical for the antitumor activity of IFNg-NGR.
Given that soluble p55 and p75 TNF receptors (sTNF-R1 and sTNF-R2, respectively) could inhibit endogenous TNF and consequently inhibit the antitumor activity of IFNg-NGR, we have addressed the hypothesis that induction of soluble TNF receptors by high doses of IFNg-NGR contributes to inhibiting its activity. Three hundred nanograms of IFNg-NGR, but not 3 ng, significantly induced sTNF-R1 and sTNF-R2 shedding in the blood of RMA tumor-bearing mice (Fig. 7B) . Thus, the release of sTNF-Rs could be one of the counterregulatory mechanisms that contribute to generate the bell-shaped dose-response curve of IFNg-NGR. This phenomenon is not a peculiarity of high doses of targeted IFNg, as nontargeted IFNg (IFNg-C136S) could also induce sTNF-R2 shedding (Fig. 7B) .
Soluble TNF-R2 shedding in mice can be induced by TNF itself (42) . To assess whether shedding of sTNF-Rs was indirectly mediated by endogenous TNF or was a direct consequence of IFNg, IFNg-induced shedding of sTNF-R2 was studied in mice pretreated with anti-TNF mAb V1q. As shown in Fig. 7B , IFNg-C136S-induced shedding of sTNF-R2 was not inhibited by V1q, pointing to a direct mechanism.
Discussion
We have found that targeted delivery of low doses of IFNg to CD13, a marker of angiogenic vessels, can delay tumor growth in murine models that respond poorly to IFNg. Targeted delivery of IFNg to CD13 was achieved by coupling the COOH terminus of IFNg to the NH 2 terminus of GCNGRC peptide, a CD13 ligand (37) . To avoid potential disulfide bridge formation between cysteine residues present in the GCNGRC targeting domain and in the NH 2 -and COOH-terminal regions of IFNg (Cys 1 , Cys 3 and Cys 136 ) we deleted the first three residues of murine IFNg and replaced Cys 136 with Ser. The results of biochemical and in vitro biological studies of the IFNg 4-135 -C136S-GCNGRC conjugate (called IFNg-NGR) showed that the final product was homogeneous and characterized by a dimeric structure with accessible and functional targeting and effector domains (i.e., GCNGRC and IFNg). The results of studies on the mechanism of action of IFNg-NGR suggest that the improved antitumor activity of this conjugate depends on the GCNGRC targeting domain, as originally postulated, and not on the C136S substitution. This view is supported by the following observations: (a) the antitumor activities of IFNg and IFNg-C136S (lacking the targeting domain) were similar and very low; (b) the in vivo antitumor activity of IFNg-NGR was almost completely inhibited by an antibody (mAb R3-63) against CD13, a CNGRC-receptor. These findings, together, support the hypothesis that IFNg-NGR works via a GCNGRC/CD13-dependent targeting mechanism.
We have previously shown that tumor-associated vessels of human breast carcinoma tissue section and other primary and metastatic tumors could be stained by immunohistochemistry with the anti-CD13 mAb WM15 (38) . The finding that IFNg-NGR can compete mAb WM15 binding to tumor vessels in tissue sections and the notion that RMA tumor cells of our murine model do not express CD13 (41) further support the CD13-mediated vascular targeting hypothesis.
Another important observation of this work is that the doseresponse curve of IFNg-NGR is bell-shaped. Maximal effects were achieved by the administration of 0.1 ng (0.005 Ag/kg) of IFNg-NGR (i.p.) in both RMA-lymphoma and WEHI-164 models, whereas administration of nontargeted IFNg induced little or no effects over a range of 0.06 to 5000 ng (0.003-250 Ag/kg). Attempts to increase the effect of IFNg-NGR by increasing the dose (up to 250 Ag/kg) or by frequent (daily) administration resulted in a decrease of activity.
The bell-shaped dose-response curve is not a peculiarity of targeted IFNg as a similar behavior has also been reported for nontargeted IFNg in other animal models and in patients (6, (31) (32) (33) . However, it is noteworthy that doses of about 2 Ag/kg of IFNg were necessary to induce maximal biological effects in patients and even higher doses (250 Ag/kg) were required in mice (6) . One explanation for the bell-shaped dose-response curve of IFNg-NGR is that low doses of this modified cytokine could activate local antitumor effects, by virtue of a targeting mechanism, without activating counterregulatory mechanisms, whereas high doses could induce counterregulatory effects that prevent its potential antitumor activity. The same phenomenon could explain the low response rates observed in animals and in patients treated with IFNg. Induction of soluble TNF receptors (sTNF-R) could be one of these counterregulatory mechanisms for the following reasons. Previous clinical studies have shown that treatment of patients suffering from metastasizing renal cell carcinoma with IFNg induces the release of endogenous TNF into the serum (59) . The known synergism between IFNg and TNF in inducing tumor and endothelial cell cytotoxicity and other antitumor effects suggest that TNF could contribute to the antitumor activity of IFNg (23, 57, 58, (60) (61) (62) . Interestingly, administration of a neutralizing anti-murine TNF mAb (mAb V1q) to our tumorbearing mice inhibited the antitumor activity of low doses of IFNg-NGR. Endogenous TNF is, therefore, indeed critical for the antitumor activity of IFNg-NGR. However, we have also found that high doses of IFNg-NGR (e.g., 300 ng), but not low doses (3 ng), could induce a significant increase of sTNF-R1 and sTNF-R2 in the circulation. Similarly, high doses of nontargeted IFNg induced sTNF-Rs. Given that the release of sTNF-Rs is an important counterregulatory mechanism for TNF (63), one possibility is that sTNF-Rs shedding contributes to the bell-shaped dose-response curve of IFNg-NGR and to the lack of effect by IFNg in our models. Of course, many other cytokines and counterregulatory mechanisms could be activated by high doses of targeted and nontargeted IFNg. Nevertheless, the observation that low doses of IFNg-NGR (0.06 and 3 ng) are sufficient to activate a TNF-dependent antitumor mechanism, whereas high doses (300 ng) are necessary to induce sTNF-Rs shedding implies that antitumor and counterregulatory mechanisms could be uncoupled by the low-dose targeting strategy. This finding offers a new rationale for targeted delivery of very low doses of cytokines to tumors.
The results have also pointed out some important limitations of IFNg-NGR that deserve to be discussed. As reported for IFNg by many investigators, we observed that daily treatments with IFNg-NGR was less effective than biweekly or weekly treatments and that, remarkably, repeated treatment inhibited the response induced by the first treatment. Previous studies have shown that the release of endogenous TNF induced by IFNg in the serum of patients with renal cell carcinoma is down-regulated by repeated application of the same dose (59) . Other studies have shown that prolonged treatment with IFNg can induce hyporesponsiveness of natural killer activity (7, 64) . It is therefore possible that excessive exposure to IFNg-NGR can induce counterregulatory mechanisms (locally and/or systemically) and/or inhibit ongoing antitumor responses. Remarkably, concern was expressed about rapid disease progression in patients with Kaposi's sarcoma or other tumors repeatedly treated with high doses of IFNg in early clinical studies (65) . In our models, the spontaneous regression occasionally observed in control groups was apparently inhibited in groups repeatedly treated with targeted IFNg, through an unknown mechanism. Therefore, dosage and schedule of Figure 7 . Circulating levels of sTNF-R1 and sTNF-R2 in RMA-tumor bearing mice after treatment with IFNg-NGR or IFNg-C136S. Animals were treated 10 days after tumor implantation with 0, 3, or 300 ng of IFNg-NGR (n = 4; A) or 5 Ag of IFNg-C136S alone or in combination with anti-TNF mAb V1q (7 Ag, given 2 hours before IFNg-C136S; n = 5; B ). Animal sera were collected 1.5 hours after treatment and serum levels of sTNF-R1 and sTNF-R2 were measured by ELISA. Figure 6 . Effect of neutralizing anti-CD13 (R3-63) and anti-TNF (V1q) mAbs on the antitumor activity of IFNg-NGR. RMA (A and B ) or WEHI-tumor-bearing mice (C and D) were treated at day 10 (RMA) or day 6 (WEHI) with IFNg-NGR alone or in combination with mAb R3-63 (anti-murine CD13 mAb), or mAb V1q (anti-murine TNF), or mAb 19E12 (anti-murine Thy 1.1, control antibody) at the doses indicated in each (five mice per group). Each mAb was given 2.5 hours before IFNg-NGR; B, 4 versus o (P < 0.05; two-tailed t test at day 14); C , 4 versus o (P < 0.05; two-tailed t test at day 13).
